A Swedish randomized screening study, which is a part of European Randomized Study of Screening for Prostate Cancer (ERSPC), reported the risks involved in diagnosing prostate cancer among men. The study included the effectiveness of intention-to-screen analysis program in terms of reducing metastatic disease at the time of diagnosis. The study found a total of 48% and 70% of different control group prostate cancers. The ERSPC study also found that the metastatic disease and the avoidance of metastatic disease are important end points of the study, and the proportion of men with metastatic disease are predicted to die of prostate cancer depending on the the diagnosis of the disease. The death rates in different cancer control arms change with mortality follow-up during the years after the 8-10 yr period. The results of ERSPC study show that over 10-yr period, the incidence of metastatic disease in men can be reduced by almost 50%.